For years the Pharma Congress has been the preeminent conference for pharmaceutical, biotech and device compliance professionals. However as more and more pharmaceutical events proliferate the PCF has determined to transform the Pharma Congress into a different type of learning experience. To that end our PCF special planning committee has been charged with the transformation of the Pharma Congress.

Pursuant to this charge our special committee has taken the following initiatives to fundamentally transform the Pharma Congress:

1. The Pharma Congress will address the top five pharmaceutical compliance issues in 2006. Harvard Law Professor Arthur Miller will facilitate the discussion of these key compliance challenges. Discussion and problem solving around these key issues will be woven throughout the conference.
   
   
2. The Pharma Congress will be interactive. In the plenary sessions each attendee will have a Meridia Audience response device with which he or she will be able to vote on questions put by the faculty. The attendee responses will be immediately projected on the session screens.
   
   
3. The Pharma Congress will be built around a sophisticated hypothetical exercise that will continue throughout the conference. The hypothetical will include a variety of factual scenarios relating to issues raised by the top five pharmaceutical compliance issues in 2006. Attendees will be challenged to apply their new knowledge to specific hypothetical fact circumstances. Results of the hypothetical will be shared on the last day of the conference.
   
   
4. Pharma Congress track session will be longer and will permit substantive learning and knowledge exchange, as well as the application of these bodies of knowledge to the changing Pharma Congress hypothetical.
   
   
5. The Pharma Congress will feature two unique networking reception opportunities. The Monday evening opening networking reception will feature an opportunity to meet a number of key Federal and state regulators and Capital Hill specializing in pharmaceutical policy. The Pharma Congress Tuesday networking reception will feature the exchange and presentation of company Codes of Conduct at poster boards throughout the Pharma Congress Exhibit Hall
   
   
6. The Pharma Congress will feature an extraordinary series of keynote speakers.

KEYNOTE SPEAKERS

Sheldon T. Bradshaw, Esq. Chief Counsel, Food and Drug Division, Washington, DC Randy Cohen Author, "The Ethicist", The New York Times Magazine, New York, NY Alice Fisher, Esq. Partner, Latham & Watkins, Former Associate Deputy Attorney General, United States Department of Justice, Washington, DC Scott Gottlieb, MD Deputy Commissioner for Medical and Scientific Affairs, Office of the Commissioner, Food and Drug Administration, Washington, DC Senator Chuck Grassley (R/IA) United States Senate, Ranking Member, Senate Finance Committee, Washington, DC Daniel R. Levinson Inspector General, Department of Health and Human Services, Washington, DC Mark B. McClellan, MD, Ph.D. (Invited) Administrator, Centers for Medicare & Medicaid Services and Former Commissioner of Food and Drugs, Food and Drug Administration, Washington, DC

Arthur Miller, Esq. Bruce Bromley Professor of Law, Harvard Law School, Cambridge, MA James Moorman President and Chief Executive Officer, Taxpayers Against Fraud, Washington, DC James Sheehan, Esq. Associate United States Attorney, U.S. Attorney's Office for the Eastern District of Pennsylvania, Philadelphia, PA Tommy Thompson Chair, Deloitte & Touche Center for Health Care Management, Partner, Akin Gump Strauss Hauer & Feld LLP and Former, Secretary of Health and Human Services, Department of Health and Human Services, Washington, DC Susan Winkler, Esq. Assistant United States Attorney, Deputy Health Care Fraud Chief, United States Attorney's Office, District of Massachusetts, Boston, MA Alan Yuspeh, JD, MBA Senior Vice President, Ethics, Compliance and Corporate Responsibility, HCA Healthcare Corporation and Former Coordinator, Defense Industry Initiative on Business Ethics and Conduct, Nashville, TN

CONGRESS CO CHAIRS

John T. Bentivoglio, Esq. Partner, King & Spalding, Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, United States Department of Justice, Washington, DC Keith M. Korenchuk, JD, MPH Partner, McGuire Woods, Charlotte, NC Arjun Rajaratnam, Esq. Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline, Research Triangle Park, NC

Brenton L. Saunders, JD, MBA Senior Vice President, Global Compliance and Business Practices, Schering-Plough Corporation, Past President, Health Care Compliance Association, Founder, International Association of Privacy Professionals, Kenilworth, NJ Bert Weinstein, Esq. Vice President, Corporate Compliance, Purdue Pharma LP, Stamford, CT

AN INVITATION TO JOIN US

We hope that you will join us and help us to transform the Pharma Congress to reflect a new style of learning and knowledge exchange. You may register on the Pharma congress website at www.PharmaCongress.com.

Sincerely,

PCF Special Pharma Congress Planning Committee:

Arjun Rajaratnam Vice President and Compliance Officer, Global Pharmaceuticals GlaxoSmithKline (Co chair) Brenton L. Saunders, JD, MBA Senior Vice President Global Compliance and Business Practices Schering-Plough Corporation (Co chair) Bert Weinstein, Esq. Vice President, Corporate Compliance Purdue Pharma LP (Co chair) John Alivernini, Esq. Vice President and Chief Compliance Officer Wyeth Pharmaceuticals John T. Bentivoglio, Esq. Partner King & Spalding LLP David B. Chandler, Ph.D., DABT Manager, Compliance 3M Pharmaceuticals Anthony L. Farino Partner, US Leader Life Sciences Advisory Practice PricewaterhouseCoopers LLP

Peter N. Grant, JD, Ph.D. President Health Care Conference Administrators, LLC Keith M. Korenchuk, JD, MPH Partner, McGuire Woods Steve Mohr, Esq. Deputy Compliance Officer AstraZeneca Lori Queisser Vice President and Chief Compliance Officer Eli Lilly and Company Catherine Sazdanoff Divisional Vice President Ethics and Compliance Abbott Laboratories Michael Shaw Deputy Compliance Officer Novartis Pharmaceuticals Corporation Paul J. Silver National Leader, Health Sciences Investigative and Dispute Services Ernst & Young LLP Jonathan K. Sprole Chief Compliance Officer Bristol-Myers Squibb Company Sheryl Vacca, CHC West Coast Life Science and Health Care Regulatory Practice Leader Deloitte & Touche LLP